Class I recalls surge as FDA struggles with resources
Supply Chain Pulse — 2026-04-26
The FDA logged a sharp uptick in Class I recalls throughout 2025, with the agency citing resource constraints as a key factor in its struggle to keep pace with safety issues. This morning brings another high-risk recall — Tandem's Mobi insulin pumps — while European regulators simultaneously update guidance on managing supply disruptions, painting a picture of global regulatory systems under strain. The convergence suggests supply chain teams should brace for more frequent safety-driven inventory pulls and tighter compliance scrutiny ahead.
Quick Hits
- FDA advances CNPV voucher system for psychedelic drug development (RAPS)
- Quasar Medical opens new manufacturing facility in Thailand (PR Newswire)
- Amcor launches advanced healthcare packaging coating plant in Malaysia (Mirage News)
- VillageReach analyzes private sector engagement in health supply chains (VillageReach)
- State PBM oversight gaps persist despite widespread regulation (Modern Healthcare)
FDA sees Class I recalls surge in 2025 amid resource crunch
The FDA reported a significant increase in Class I recalls throughout 2025, with agency officials attributing the trend to ongoing resource and staffing challenges. This spike in the most serious recall category means supply chain managers should expect more frequent emergency inventory pulls and heightened scrutiny of supplier quality systems. The timing coincides with several high-profile device recalls, suggesting systematic pressure on the FDA's ability to catch safety issues before they reach patients.
FDA flags high-risk recall for Tandem diabetes Mobi pumps
Tandem Diabetes Care's Mobi insulin pumps are under a high-risk FDA recall, adding another device to this year's growing list of Class I safety actions. For supply chain teams managing diabetes care products, this recall underscores the critical importance of having backup suppliers and rapid communication protocols with clinical staff. The Mobi system's recall comes as hospitals increasingly rely on connected diabetes management devices.
European regulators update device classification and supply disruption guidance
The Medical Device Coordination Group released updated guidance covering device classification, supply disruption management, and the European Medical Device Nomenclature system. These changes will directly impact how EU-based suppliers and their US hospital customers navigate regulatory compliance and inventory planning. Supply chain professionals should review these updates now, as they'll influence vendor qualification processes and emergency procurement protocols.
FDA FY27 budget breakdown reveals ambitious regulatory priorities
The FDA's proposed FY27 budget outlines expanded enforcement capabilities and new regulatory initiatives that will shape supply chain compliance requirements. Key areas include enhanced device oversight, supply chain security measures, and accelerated review processes that could impact procurement timelines. Supply chain leaders should monitor these budget priorities as they translate into new inspection protocols and vendor requirements over the next 18 months.
New insurance product launches to cover medical device recalls
A managing general agent has launched specialized insurance coverage for medical device recalls, responding to the surge in safety-related product withdrawals. This product could help hospitals and device manufacturers offset the significant costs associated with Class I recalls, including product replacement, clinical monitoring, and legal exposure. The timing suggests insurers see device recall risk as a growing market opportunity worth covering.
Asahi Kasei completes €780M acquisition of German pharma company Aicuris
Japanese conglomerate Asahi Kasei has finalized its €780 million ($920.7M) acquisition of German antiviral specialist Aicuris, expanding its pharmaceutical manufacturing footprint in Europe. This deal could create new supply chain opportunities for hospitals sourcing antiviral medications, particularly as Asahi Kasei integrates Aicuris' specialized manufacturing capabilities. The acquisition reflects continued consolidation in the pharma sector that often leads to supply chain disruptions during integration periods.
Source: Pharmaceutical Business Review
Community Health Systems expands surgery center portfolio
Community Health Systems continues its acquisition spree in the ambulatory surgery center space, adding new facilities to its growing portfolio. This expansion trend among large health systems is creating new procurement opportunities and economies of scale for surgical supply vendors. Supply chain professionals should track these consolidation moves as they often trigger contract renegotiations and standardization initiatives across newly integrated facilities.
India launches digital platform to unify drug regulation across states
India is developing a centralized digital platform to harmonize drug regulation between federal and state authorities, potentially streamlining pharmaceutical supply chains serving the world's largest democracy. This regulatory modernization could improve transparency and reduce compliance complexity for global pharma companies operating in India. US hospitals sourcing generic drugs from Indian manufacturers should monitor this initiative as it may affect approval timelines and quality oversight.
You're receiving this because you subscribed to Supply Chain Pulse, a daily brief for healthcare supply chain professionals. Unsubscribe